GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » Buildings And Improvements

CLVSF (CellaVision AB) Buildings And Improvements : $1.63 Mil (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB Buildings And Improvements?

CellaVision AB's quarterly buildings and improvements increased from Sep. 2024 ($2.10 Mil) to Dec. 2024 ($6.32 Mil) but then declined from Dec. 2024 ($6.32 Mil) to Mar. 2025 ($1.63 Mil).

CellaVision AB's annual buildings and improvements increased from Dec. 2022 ($6.40 Mil) to Dec. 2023 ($6.77 Mil) but then declined from Dec. 2023 ($6.77 Mil) to Dec. 2024 ($6.32 Mil).


CellaVision AB Buildings And Improvements Historical Data

The historical data trend for CellaVision AB's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Buildings And Improvements Chart

CellaVision AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.20 7.65 6.40 6.77 6.32

CellaVision AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 2.29 2.10 6.32 1.63

CellaVision AB Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.

CellaVision AB Headlines

From GuruFocus

Q3 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2024 CellaVision AB Earnings Call Transcript

By GuruFocus News 10-25-2024

Q4 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 02-10-2024

Q3 2019 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q1 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q2 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024